Results 161 to 170 of about 153,411 (218)

The Role of Belatacept‐Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation

open access: yesTransplant Infectious Disease, EarlyView.
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam   +5 more
wiley   +1 more source

HHV‐8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions

open access: yesTransplant Infectious Disease, EarlyView.
Risk mitigation strategies, including donors/recipients screening, DNAemia monitoring in recipients at risk, CNI‐to‐mTOR inhibitors switch, antivirals, and rituximab for KICS, may mitigate the impact of HHV‐8/KSHV infection in SOT. This review provides an update on KICS, identifies research gaps, and summarizes advances in screening and management ...
Alessandra Mularoni   +9 more
wiley   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Clinical implications of imlifidase interference in antibody screening and transfusion management

open access: yesTransfusion, EarlyView.
Abstract Background Imlifidase has received conditional approval from the EMA for desensitizing deceased donor kidney transplant recipients. It works by cleaving IgG into F(ab′)2 and Fc fragments, thereby reducing the risk of antibody‐mediated rejection. However, its impact on diagnostic assays remains understudied. Case Report We present the case of a
Zgjim Osmani   +2 more
wiley   +1 more source

Survey of quality control testing practices on low titer group O whole blood in the United States

open access: yesTransfusion, EarlyView.
Abstract Background Use of low titer group O whole blood (LTOWB) continues to increase in the United States (US). This survey sampled the quality control (QC) practices among the largest blood collectors in the US. Methods A survey on LTOWB collection, QC testing, and distribution was developed and electronically distributed to the chief medical ...
Mark H. Yazer   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy